中医综合治疗方案联合TACE治疗中晚期原发性肝癌的临床观察  

Clinical Observation of Comprehensive Treatment of Traditional Chinese Medicine combined with TACE in Advanced Primary Hepatic Carcinoma Patients

作　　者：彭巍[1] 蒋益兰[1] 邓湘生[1] 高文辉 PENG Wei;JIANG Yi-lan;DENG Xiang-sheng;GAO Wen-hui(The Affiliated Hospital of Hu＇nan Ae,ade,my of Chinese Medicine,Changsha Hu＇nan 410006 China)

机构地区：[1]湖南省中医药研究院附属医院,湖南长沙410006

出　　处：《中医药导报》2018年第18期28-31,共4页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：湖南省中医药科研计划项目(201117)

摘　　要：目的:研究中医药联合TACE方案治疗中晚期原发性肝癌患者的临床疗效及安全性。方法:采用非随机同期对照研究方法,将96例中晚期原发性肝癌患者分为综合治疗组、中医药组、TACE组,每组32例,中医药组予中药汤剂、中成药、中药注射液和中医外治等中医药综合方案治疗;TACE组予肝动脉灌注化疗栓塞(TACE);综合治疗组采用中医药综合治疗联合TACE治疗。观察3组患者治疗前后临床症状评分、中医证候疗效、KPS评分、实体瘤疗效、无进展生存期(PFS)、总生存期(OS)、不良反应等情况。结果:3组患者临床症状积分均较治疗前降低(P<0.01);治疗后3组比较,综合治疗组临床症状积分低于中医药组、TACE组(P<0.05),中医药组临床症状积分低于TACE组(P<0.05);3组中医证候疗效比较,综合治疗组优于TACE组(P<0.01),中医药组优于TACE组(P<0.05);综合治疗组优于中医药组(P<0.05);3组生活质量比较,综合治疗组KPS评分优于TACE组(P<0.05);综合治疗组中位PFS为8.31个月,中医药组中位PFS为4.72个月,TACE组中位PFS为5.69个月,综合治疗组明显优于中医药组、TACE组(P<0.05);综合治疗组中位OS为17.78个月,中医药组中位OS为10.81个月,TACE组中位OS为11.94个月,3组中位OS比较,综合治疗组明显优于中医药组、TACE组(P<0.05);3组不良反应比较,中医药组未见明显不良反应,综合治疗组不良反应明显低于TACE组(P<0.01)。结论:中医药综合治疗方案联合TACE可有效改善中晚期原发性肝癌患者临床症状,稳定瘤体,降低不良反应,提高患者生活质量,在一定程度上延长生存期,是原发性中晚期肝癌安全有效的综合治疗手段。Objective： To study the clinical efficacy and safety of traditional Chinese medicine combined with TACE in the treatment of patients with advanced primary hepatic carcinoma. Methods： A non-randomized concurrent control study method was applied to 96 patients with advanced primary hepatic carcinoma. Patients were divided into comprehensive treatment group, Chinese medicine group, TACE group（32 cases in each group）;Chinese medicine group received comprehensive treatment of TCM medicine treatment, including decoction of traditional Chinese medicine, oral medicine, Chinese medicine injection therapy, external therapy of traditional Chinese medicine etc. TACE group was treated with transcatheter hepatic arterial chemoembolization（TACE）.Comprehensive treatment group was given treatment of traditional Chinese medicine combined with TACE treatment. Observe three groups of patients before and after treatment of clinical symptoms, TCM syndrome curative effect, curative effect, KPS score, tumor progression free survival（PFS） and overall survival（OS） survival rate, adverse reactions. Results： The scores of clinical symptoms in the three groups were lower than those before treatment（P〈0.01）, the scores of clinical symptoms in the comprehensive treatment group were lower than those in the traditional Chinese medicine group and TACE group（P〈0.05）, and the scores of clinical symptoms in the traditional Chinese medicine group were lower than those in the TACE group（P〈0.05）. Comparing the curative effect of three groups of TCM syndromes, the comprehensive treatment group was superior to the TACE group（P〈0.01）, the TCM group was superior to the TACE group（P〈0.05）, and the comprehensive treatment group was superior to the TCM group（P〈0.05）. The KPS scores of the 3 groups were better than those of the TACE group（P〈0.05）. The median PFS was 8.31 months in the comprehensive treatment group, 4.72 months in the traditional Chinese medicine group and 5.69 months in the TACE g

关 键 词：原发性肝癌 中晚期 综合治疗 中医药 肝动脉灌注化疗栓塞 

分 类 号：R273[医药卫生—中西医结合]